Pharmaceutical TechnologyOriginal article
BioMarin spends up to $490m for Alesta’s bone disease candidate
Alesta bone disease candidateStrensiqPositive
AI Analysis
Summary
BioMarin Pharmaceutical acquired Alesta Therapeutics' bone disease candidate for up to $490 million, providing a potential competitor to AstraZeneca's Strensiq in the hypophosphatasia market.
Importance:7/10
Sentiment:
0.60
M&Aacquisitionbone diseasehypophosphatasiacompetitive positioning
Related Companies
Read the original article
Published by Pharmaceutical Technology on August 19, 2026 1:55 PM